Marking Techniques for Targeted Axillary Dissection Among Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy

Abstract

Invasive breast cancer with axillary lymph node (LN) invasion is a continuing problem worldwide. The morbidity associated with axillary LN dissection along with the high rate of nodal downstaging after neoadjuvant chemotherapy (NACT) made the standard treatment shift towards less invasive surgery. Sentinel lymph node biopsy (SLNB) after NACT is associated with high false-negative rates (13%-14%). To overcome this problem, it was concluded that the positive nodes should first be indicated with image-detectable markers and then removed together with SLNB: targeted axillary dissection (TAD). This review aims to describe and evaluate the different marking techniques for TAD in patients with node-positive breast cancer treated with NACT, namely: clip placement and guidewire localization; clip placement and 125I-labelled radioactive seed localization; clip placement and skin mark; clip placement and intraoperative ultrasound; tattooing with a sterile black carbon suspension; magnetic seeds; radar and infrared light technology localization. Targeted axillary dissection techniques have shown false-negative rates below 9% and identification rates above 95%. The most studied technique is guidewire localization, as it is also the oldest one. However, according to data gathered from this review, some newer techniques have shown to be very promising due to their statistical results and management factors.

Keywords

Breast neoplasms lymphatic metastasis neoadjuvant therapy targeted axillary dissection

Introduction

Over the last century, surgical procedures in breast cancer patients have evolved from being disfiguring to relatively noninvasive.¹ The management of invasive breast cancer involves the effort of a multidisciplinary team to establish a correct diagnosis and staging.² Not only the type of systemic therapy, surgery, and radiation is decided according to the lymph node (LN) status but also the prognosis depends on the presence of nodal metastases.^3
-6 In breast cancer patients with axillary metastasis, neoadjuvant chemotherapy (NACT) results in a complete pathological response in a still growing number of patients, which is due to improvements in the systemic treatments, mainly for triple-negative and human epidermal growth factor receptor 2 (HER2+) subtypes.⁴ The high rate of nodal downstaging has led to the acceptance of sentinel lymph node biopsy (SLNB) to stage the axilla after NACT in patients who had a clinical and radiological complete response (40%-75%).^4,7 Such paradigm shift allowed avoiding most axillary lymph node dissections (ALNDs) after NACT and its morbidity effects such as pain, paraesthesia, shoulder dysfunction and, more significantly, lymphoedema.^8,9 Therefore, management of the axilla has shifted into a less radical and less invasive approach. Furthermore, in line with the ACOSOG Z0011 and AMAROS clinical trials, which showed no benefit of the completion ALND in selected patients with positive sentinel LN(s), current guidelines state that SLNB is sufficient, even in the case of nodal involvement, in most patients with small tumours who are receiving adjuvant therapies.^10
-12

However, SLNB alone after NACT has a high false-negative rate (13%-14%) and, when the initially metastatic LN is marked, the sentinel LNs did not correspond to it in 23%.^7,13 As the sentinel LN is the hypothetical first LN (or group of nodes) to which a cancer can drain to, this means that other nodes in the axilla can have residual disease, reinforcing the idea that SLNB is not enough to achieve the desired detection results. This also suggests that NACT can alter axillary lymphatic drainage pathways, leading to high false-negative rate (FNR).¹⁴ To overcome these issues, the positive nodes should be marked before NACT, with an image-detectable marker, and then removed together with SLNB after NACT – targeted axillary dissection (TAD). After Caudle et al³ showed that adding the excision of the clipped node to the SLNB was able to reduce the FNR to 1.4%, this strategy has been endorsed by some guidelines.^10,13 In fact, with an FNR of 2%, oncological compromise would only affect approximately 1 in 10 000 patients, which does not justify the need for a more invasive strategy.¹³

The best technique for TAD in patients with initially node-positive breast cancer who are clinically negative after NACT is still unclear. This review aims to describe and evaluate the different marking techniques for TAD in patients with node-positive breast cancer treated with NACT. The techniques will be compared for feasibility, advantages and disadvantages, specific side effects, identification rates (IRs) and false-negative rates. In addition, it will be briefly discussed in which sense these techniques can improve the treatment and quality of life of these patients.

Materials and Methods

An online search was conducted at PubMed with the search equation: ‘Breast Neoplasms’ [Mesh] AND neoadjuvant AND axilla*. The search was restricted to articles written in English, published in the period from 2010 to 2021. All types of articles were selected for review. Approximately 800 published articles were assessed. The studies considered relevant from the bibliographic references of the selected articles were also analysed. A total of 32 articles were selected as relevant references for this review, with preference for the most up-to-date literature.

Comparison of Technologies

Clip placement and guidewire localization

This technique, which has been used to localize nonpalpable lesions in the breast, could be adapted to use in the preoperative image-guided localization of axillary LNs.⁴ To correctly allocate the wire, mammography, ultrasound (US), and magnetic resonance imaging (MRI) can help localizing the LNs.⁴ The low price point and the familiar, yet complex, surgeons and radiologists’ workflow may seem the primary benefits of this technology. Due to the risk of migration, the placement and removal must be performed on the same day.^4,15,16 The wire is easily visualized protruding from the skin and can be followed by the surgeon to reach the targeted LN.⁴ There has been some hesitation (both from radiologists and surgeons) to use these wires due to its known complications such as pain, hematoma, and adjacent tissue injury.⁴ It was demonstrated a good concordance between the retrieval of the clipped node and the sentinel lymph node (SLN) (86%) associated with an accurate retrieval of the clipped node (92%).⁹ The clipped node IR was of 97% when wire localization was used.^9,11

Clip placement and 125I-labelled radioactive seed localization

The use of labelled radioactive seeds as a localization technique was initially designed for nonpalpable lesions in the breast. However, it is currently being adapted for the axilla.⁴ The radioactivity level within the 125I-seed ranges from 0.1 to 0.3 millicuries, with a half-life of 60 days, which makes the scheduling of surgery easier besides being considered safe for human exposure.^4,16 This technique’s advantages include decreased risk of displacement, better patient comfort and lower potential of injuries to the surrounding vascular structures during surgery.¹⁶ Concerning the drawbacks, the most obvious is the exposure to radiation. It is not only an expensive and a complicated procedure, but it also faces legal problems for retrieval and disposal of radioactive materials. ^4,15 It also requires the involvement of a nuclear physician and does not provide real-time visual guidance.¹⁷ Nevertheless, the dose of radiation is small, and there is no significant exposure to people who may come into contact with the patient before or after surgery.⁴ Seed loss, the need for special instruments to identify the seeds and seed migration are other potential disadvantages of this technique.^9,18 Applying a marker clip to LNs under US guidance and then marking these LNs post-NACT with radioactive I125-seeds achieved an IR of 96.7% and concordance among clipped LNs and SLNs reached 91%.^19,20 The clipped node was associated with FNR of 4.2%, and specifically localizing and removing the clipped node in addition to removal of SLNs resulted in an FNR of 2.0%.¹⁶

Clip placement and skin mark clipped axillary nodes

Preoperatively, the clip localization was marked on the skin with the arm abducted at 90°, with an US probe placed perpendicularly to the skin. Then, a 21G needle is inserted perpendicularly into the skin to place the clip. Identification of the clip was based on its perpendicular distance from the skin, and morphology and position were determined relatively to surrounding structures based on pre-NACT diagnostic US.⁷ In the SMART trial, there were no complications with the clip placement. Despite its different types, the one that had the highest rate of identification was the UltraCor Twirl (100%), mainly due to the improvements in its US visibility.^7,21 When comparing to the visibility of other clips, these are still suboptimal, with reported rates of only 72% to 83%. This is mainly due to the NACT that causes shrinkage and fibrosis of the LNs, making them less hypoechogenic on US and harder to identify against a background of echogenic fat.⁷ The advantages of this technique include it being noninvasive, wireless and radiation-free. It is also less expensive than other localizing devices and more accessible to health centres.⁷ No complications of this technique were reported. Limitations of SMART trial included a small sample size and, as all patients underwent ALND, it was not possible to assess the compatibility with SLNB and to evaluate the FNR.⁷

Clip placement and intraoperative US

Size, morphology, internal echogenicity, disproportionate enlargement, presence of eccentric or uneven cortical thickening and abnormal ‘rounding’ shape are sonographic features that characterize malignant LNs¹⁶ (Figure 1).

Figure 1.

Metastatic LN marked with a clip (yellow arrow), before NACT.

However, the Z1071 trial exposed evidence demonstrating that US is not a precise method for identifying normalized axillary nodes following NACT as more than 50% of cases are still pathologically positive.²² It also concluded that TAD is a more accurate procedure for staging the LNs after NACT.^2,9,22 This led to the use of marker clips to be identified by US. These can be divided in 2 categories: a metallic clip typically made of stainless steel or titanium and a sonographically visible metallic clip with an associated bioresorbable material typically made of collagen, polylactic acid, or polyglycolic acid, which absorbs water over time.⁴ Although some studies refer this technique to not have any problems regarding clip migration or complications related to the clip insertion or patient distress, others are worried about the possibility of migration and extrusion.^23,24 This is a situation that can happen in 50% of procedures using sonographically visible water-absorbing clips.⁴ Nevertheless, there is the advantage of the time that a clip can remain visible, making the scheduling of surgeries and clip placement much easier.^4,24 In addition, it is also a very cost-effective technique, and in re-excision rates, it can be superior to wire localization.²⁵ The technique is very safe in experienced hands, with close to a 100% success rate.^7,24 In 1 study, 95.7% marker clips were identified preoperatively and successfully removed using intraoperative US; in the remaining patients, the HydroMARK clip was successfully removed after ALND.⁴ This suggests that sonographically visible hygroscopic or metallic clips could be a reasonable choice for use in intraoperative US axillary localizations.⁴

Tattooing with a sterile black carbon suspension

For tattooing, black ink was injected adjacent to the soft tissue and into the cortex of the node through US guidance. The radiologist marked the location of the LN on the skin with an oil-based pen to guide the surgical incision.^26,27 Tattooing with activated charcoal has been reported to yield high IRs in preceding studies of 95% to 100%,^19,26
-28 Black ink has the advantage of being identified up to an average of 130 days^19,27,28 as well as being an affordable alternative to the already existing methods.¹⁹ It is also unnecessary to verify the removal of a clip or radioactive seed during surgery.²⁷ There is also some clinically negligible risk of charcoal absorption or migration and the long-term complications of tattooing should be further validated using cohort studies.²⁷ The diagnostic performance of TAD using sterile black carbon suspension showed values as follows: FNR 8.3% and accuracy 95%. Concordance among tattooed LNs and SLNs is not absolute, indicating an improvement in the accuracy of post-NACT SLNB with the help of TAD as this technique selects to remove marked LNs not supposed to be SLNs.¹⁹

Magnetic seeds

The magnetic seed uses a 1 × 5 mm surgical stainless-steel marker.^4,29 It can be detected using a magnetometer (Sentimag^®), which provides information about how far away it is and its direction to the marker.¹⁸ Seed placement performed under US guidance is similar to sonographically guided clip placement. The seed is localized in the operating room using the Sentimag^® magnetometer.^4,18 Magseed^® appears to be an accurate, safe and nonradioactive method for precisely localizing axillary LNs, with 97% of target LNs being successfully removed in surgery.¹⁸ On a trial, seed loss was reported in 1 patient. Besides that, no documented complications occurred.¹⁸ Major disadvantages of using magnetic seeds are the cost of each seed and depth limitation.^9,18,30

Radar and infrared light technology localization

Nonradioactive infrared (NIR)–activated electromagnetic wave reflector is implanted under imaging guidance, and an audible signal from the implanted reflector is then detected percutaneously using the manufacturer’s system.^4,15,31 The use of NIR fluorescence for SLN mapping has several advantages over conventional modalities such as real-time visual guidance, superior depth penetration, as well as broader availability compared with radioactive tracers.¹⁷ Also, the reflector is approved for long-term placement so it could be placed before the NACT. Due to its scheduling benefits, lower levels of anxiety, better comfort and improved clinical management were achieved.³² No cases of reflector migration were reported.^4,15 Considering the greater scheduling flexibility, shorter operating times, lower re-excision rates and reduced deployment times, it may be possible to make some indirect financial savings due to its effectiveness in spite of its initial higher and recurrent cost.³² The clip is 12 mm long which is relatively large compared with the normal-sized LNs. This may cause some uncertainty regarding the placement as it may need to be placed adjacent to an abnormal LN.^4,15 Savi SCOUT^®, which is an approved console to detect reflectors’ localization, was successful in 97% (125 of 129; 95% confidence interval [CI] = 92%-99%) patients. Of the 4 unsuccessful cases, 3 were due to an inability to obtain an audible signal.³¹ Nonetheless, this indicates that this technology is highly accurate and may help to successfully retrieve metastatic nodes and facilitate surgical planning in the axilla.⁴ It was reported a re-excision rate of 12.8% (Table 1).¹⁵

Table 1.

Comparison of targeted axillary dissection techniques.

Techniques	Timing of device placement	Advantages	Disadvantages	FNR	IR
Guidewire^4,9,11,15,16	Immediately prior to surgery	Low price Familiar workflow Nonradioactive	Potential damage of adjacent structures Pain, hematoma	6.8%	97%
I-125 radioactive seed^4,15 -20	5-7 days prior to surgery	Decreased risk of displacement Patient comfort Decreased risk of damaging adjacent structurers	Radiation Legal and regulatory complications Seed loss Special instruments Seed migration	4.2%	96.7%
Skin mark^7,21	Immediately prior to surgery	Low price Nonradioactive Wireless	Risk of migration and extrusion of the clip	N/A	100% (with UltraCor Twirl clip)
Intraoperative US^{2,4,7,9,16,22 -25}	At time of biopsy	No patient distress Clip visible for long time Cost-effective Good re-excision rates Nonradioactive	Risk of migration and extrusion of the clip	7%	95.7%
Sterile black carbon suspension^19,26 -28	At time of biopsy	Average duration of 130 days Affordable Nonradioactive	Potential difficult visualization due to charcoal absorption or migration	8.3%	95%-100%
Magnetic seed^4,9,18,29,30	At least up to 30 days prior to surgery	Accurate Safe Nonradioactive No restriction on duration	Cost Depth limitation MRI artefact	1.4%	97%-100%
Radar and infrared light^{4,15,17,31,32}	At time of biopsy	Real-time visual guidance Superior depth Nonradioactive No restriction on duration	Contains nickel Structures may impede signal	N/A	97%

Abbreviations: FNR, false-negative rate; IR, identification rate; MRI, magnetic resonance imaging; N/A, not available; US, ultrasound.

Conclusions

Identifying metastatic nodes in the axilla after NACT is of the outmost importance in medical practice today. Therefore, there is an attempt to improve its current techniques. This is a necessity that arose from the limitations of the standard SLNB presenting an FNR above 10%, making it unsuitable for safely staging breast cancer patients.

To overcome this problem, several marking techniques for TAD were developed: clip placement and guidewire localization; clip placement and 125I-labelled radioactive seed localization; clip placement and skin mark; clip placement and intraoperative US; tattooing with a sterile black carbon suspension; magnetic seeds; radar and infrared light technology localization. Globally, TAD has presented FNR below 9% and IR above 95%. The most studied technique is guidewire localization as it is also the oldest one. However, according to data gathered from this review, some techniques have shown to be very promising due to their statistical results and management factors. For example, tattooing with a sterile black carbon suspension or clip placement and skin mark clipped axillary nodes could be a more practical option. They both performed equal or above the other techniques while only requiring the clip or the ink and US technology to place it correctly. The US component is a well-known technology which most health facilities have access to, besides being a more affordable option.

Even though it has been understood that TAD is more precise than SLNB alone, to better understand this procedure and maximize its potential, more studies need to be conducted, including larger number of patients.

Footnotes

Acknowledgements

Not applicable.

Declarations

References

Moncayo

Grady

Alazraki

Aarsvold

. Sentinel-lymph-node multicenter trials. Semin Nucl Med. 2020;50:56-74. doi:10.1053/j.semnuclmed.2019.10.001.

Racz

Caudle

. Sentinel node lymph node surgery after neoadjuvant therapy: principles and techniques. Ann Surg Oncol. 2019;26:3040-3045. doi:10.1245/s10434-019-07591-6.

Caudle

Yang

Krishnamurthy

, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072-1078. doi:10.1200/JCO.2015.64.0094.

Woods

Camp

Durr

Harvey

. A review of options for localization of axillary lymph nodes in the treatment of invasive breast cancer. Acad Radiol. 2019;26:805-819. doi:10.1016/j.acra.2018.07.002.

Ahmed

Douek

. Targeted axillary dissection after neoadjuvant therapy in breast cancer. Br J Surg. 2018;105:313-314. doi:10.1002/bjs.10626.

de Boniface

Frisell

Andersson

, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:1-7. doi:10.1186/s12885-017-3361-y.

Lim

Teo

Gudi

, et al. Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: skin mark clipped axillary nodes removal technique (SMART trial). Cancer Med. 2020;9:1978-1985. doi:10.1002/cam4.2848.

Alvarado

Mittendorf

Teshome

, et al. SentimagIC: a non-inferiority trial comparing superparamagnetic iron oxide versus technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early-stage breast cancer. Ann Surg Oncol. 2019;26:3510-3516. doi:10.1245/s10434-019-07577-4.

Balasubramanian

Morgan

Shaari

, et al. Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy. Eur J Surg Oncol. 2020;46:1028-1033. doi:10.1016/J.EJSO.2019.12.007.

10.

Banys-Paluchowski

Gruber

Hartkopf

, et al. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature. Arch Gynecol Obstet. 2020;301:341-353. doi:10.1007/s00404-019-05428-x.

11.

Giuliano

McCall

Beitsch

, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American college of surgeons oncology group z0011 randomized trial. Ann Surg. 2010;252:426-432. doi:10.1097/SLA.0b013e3181f08f32.

12.

Donker

van Tienhoven

Straver

, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-1310. doi:10.1016/S1470-2045(14)70460-7.

13.

Wazir

Mokbel

. De-escalation of axillary surgery in the neoadjuvant chemotherapy (NACT) setting for breast cancer: is it oncologically safe. Anticancer Res. 2020;40:5351-5354. doi:10.21873/anticanres.14542.

14.

García-Moreno

Benjumeda-Gonzalez

Amerigo-Góngora

Landra-Dulanto

Gonzalez-Corena

Gomez-Menchero

. Targeted axillary dissection in breast cancer by marking lymph node metastasis with a magnetic seed before starting neoadjuvant treatment. J Surg Case Rep. 2019;2019:rjz344. doi:10.1093/JSCR/RJZ344.

15.

Kasem

Mokbel

. Savi scout® radar localisation of non-palpable breast lesions: systematic review and pooled analysis of 842 cases. Anticancer Res. 2020;40:3633-3643. doi:10.21873/ANTICANRES.14352.

16.

Ersoy

Kadioglu

. Review of novel sentinel lymph node biopsy techniques in breast cancer patients treated with neoadjuvant chemotherapy. Clin Breast Cancer. 2018;18:e555-e559. doi:10.1016/j.clbc.2018.01.004.

17.

Verbeek

Troyan

Mieog

, et al. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res Treat. 2014;143:333-342. doi:10.1007/s10549-013-2802-9.

18.

Greenwood

Wong

Mukhtar

Alvarado

Price

. Feasibility of magnetic seeds for preoperative localization of axillary lymph nodes in breast cancer treatment. AJR Am J Roentgenol. 2019;213:953-957. doi:10.2214/AJR.19.21378.

19.

Khallaf

Wessam

Abdoon

. Targeted axillary dissection of carbon-tattooed metastatic lymph nodes in combination with post-neo-adjuvant sentinel lymph node biopsy using 1% methylene blue in breast cancer patients. Breast J. 2020;26:1061-1063. doi:10.1111/tbj.13736.

20.

Diego

McAuliffe

Soran

, et al. Axillary staging after neoadjuvant chemotherapy for breast cancer: a pilot study combining sentinel lymph node biopsy with radioactive seed localization of pre-treatment positive axillary lymph nodes. Ann Surg Oncol. 2016;23:1549-1553. doi:10.1245/S10434-015-5052-8.

21.

Wang

, et al. Subtype-guided 18 F-FDG PET/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study. Oncologist. 2020;25:e626-e633. doi:10.1634/theoncologist.2019-0583.

22.

Boughey

Suman

Mittendorf

, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310:1455-1461. doi:10.1001/JAMA.2013.278932.

23.

Youn

Choi

Kook

, et al. Ultrasonography-guided surgical clip placement for tumor localization in patients undergoing neoadjuvant chemotherapy for breast cancer. J Breast Cancer. 2015;18:44-49. doi:10.4048/jbc.2015.18.1.44.

24.

Carmon

Olsha

Gekhtman

, et al. Detectability of hygroscopic clips used in breast cancer surgery. J Med Ultrasound. 2017;36:401-408. doi:10.7863/ultra.16.02053.

25.

Konen

Murphy

Berkman

Ahern

Sowden

. Intraoperative ultrasound guidance with an ultrasound-visible clip: a practical and cost-effective option for breast cancer localization. J Ultrasound Med. 2020;39:911-917. doi:10.1002/jum.15172.

26.

Kim

, et al. Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study. BMC Cancer. 2019;19:1-8. doi:10.1186/s12885-019-6095-1.

27.

Park

Koo

Kim

, et al. Feasibility of charcoal tattooing of cytology-proven metastatic axillary lymph node at diagnosis and sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients. Cancer Res Treat. 2018;50:801-812. doi:10.4143/crt.2017.210.

28.

Choy

Lipson

Porter

, et al. Initial results with preoperative tattooing of biopsied axillary lymph nodes and correlation to sentinel lymph nodes in breast cancer patients. Ann Surg Oncol. 2015;22:377-382. doi:10.1245/s10434-014-4034-6.

29.

Martínez

Roselló

Gómez

, et al. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2020;36:28-33. doi:10.1016/j.suronc.2020.11.013.

30.

Hersi

Eriksson

Ramos

Abdsaleh

Wärnberg

Karakatsanis

. A combined, totally magnetic technique with a magnetic marker for non-palpable tumour localization and superparamagnetic iron oxide nanoparticles for sentinel lymph node detection in breast cancer surgery. Eur J Surg Oncol. 2019;45:544-549. doi:10.1016/j.ejso.2018.10.064.

31.

Falcon

Weinfurtner

Mooney

Niell

. SAVI SCOUT® localization of breast lesions as a practical alternative to wires: outcomes and suggestions for trouble-shooting. Clin Imaging. 2018;52:280-286. doi:10.1016/j.clinimag.2018.07.008.

32.

Cox

Russell

Prowler

, et al. A prospective, single arm, multi-site, clinical evaluation of a nonradioactive surgical guidance technology for the location of nonpalpable breast lesions during excision. Ann Surg Oncol. 2016;23:3168-3174. doi:10.1245/s10434-016-5405-y.